Gepotidacin对比呋喃妥因治疗单纯性尿路感染的亚组分析
两项3期试验(EAGLE-2/EAGLE-3)的汇总分析显示,在呋喃妥因敏感和耐药(NTF-NS)的单纯性尿路感染女性中,Gepotidacin治疗成功率普遍高于呋喃妥因;NTF-NS人群中治疗成功差异达20.8%。
要点
- NTF-NS人群Gepotidacin治疗成功差异20.8%(95%CI 9.2-32.4),高于NTF-S的9.6%。
- 在高耐药风险亚组(年龄>50岁、复发性uUTI、糖尿病等)Gepotidacin成功率相似或更高。
- 临床成功差异在NTF-NS为10.3%(95%CI -1.4-22.1),微生物学成功差异20.7%。
核心结论
- Gepotidacin在呋喃妥因敏感和耐药uUTI患者中均显示疗效,且治疗成功率普遍高于呋喃妥因。
研究设计与样本
- 两项3期随机试验(EAGLE-2和EAGLE-3)的汇总分析,纳入≥12岁女性uUTI患者,Gepotidacin 1500 mg或呋喃妥因100 mg每日两次口服5天。
主要发现
- 在micro-ITT NTF-S人群中,治疗成功差异9.6%(95%CI 4.1-15.2),临床成功差异2.8%(95%CI -2.4-8.1),微生物学成功差异10.4%(95%CI 5.2-15.6)。
- 在micro-ITT NTF-NS人群中,治疗成功差异20.8%(95%CI 9.2-32.4),临床成功差异10.3%(95%CI -1.4-22.1),微生物学成功差异20.7%(95%CI 9.2-32.3)。
- 在高耐药风险亚组(年龄>50岁、复发性uUTI、糖尿病、轻度肾功能不全、产ESBL或氟喹诺酮耐药菌株)中,Gepotidacin成功率相似或高于呋喃妥因。
临床怎么用
- 对于呋喃妥因不敏感或高耐药风险的uUTI患者,Gepotidacin可能提供更高的治疗成功率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two phase 3 trials (EAGLE-2 [NCT04020341]/EAGLE-3 [NCT04187144]) demonstrated the efficacy of gepotidacin, a novel, first-in-class triazaacenaphthylene antibacterial, versus nitrofurantoin for the treatment of uncomplicated urinary tract infections (uUTIs). Using pooled data, we assessed gepotidacin efficacy across clinically important subgroups, including participants with nitrofurantoin not-susceptible (NTF-NS; ie, resistant, intermediate or no interpretation) uropathogens. METHODS: Female participants aged ≥12 years with uUTI received gepotidacin (1500 mg) or nitrofurantoin (100 mg), both twice daily for 5 days. Therapeutic success at test-of-cure (day 10-13) was defined as combined complete symptom resolution (clinical success) and reduction of baseline qualifying uropathogens from ≥105 to <103 CFU/mL (microbiological success), without other systemic antibacterials. Response rates at test-of-cure were descriptively summarized in the pooled microbiological intent-to-treat (micro-ITT) nitrofurantoin-susceptible (NTF-S) and NTF-NS populations, and across prespecified subgroups. RESULTS: In the micro-ITT NTF-S population, treatment differences (in favor of gepotidacin) [95% confidence interval] for therapeutic, clinical and microbiological success were: 9.6% [4.1, 15.2], 2.8% [-2.4, 8.1], and 10.4% [5.2, 15.6]. Corresponding treatment differences were higher in the micro-ITT NTF-NS population: 20.8% [9.2, 32.4], 10.3% [-1.4, 22.1], 20.7% [9.2, 32.3]. In both of these populations, gepotidacin success rates (all endpoints) were similar to or higher than nitrofurantoin across prespecified subgroups at higher risk for antimicrobial resistant uropathogens (age >50 years, history of recurrent uUTI, diabetes, mild renal impairment, extended-spectrum β-lactamase-producing or fluoroquinolone-resistant uropathogens). CONCLUSIONS: Gepotidacin demonstrated efficacy with generally higher therapeutic success rates versus nitrofurantoin in participants with NTF-S and NTF-NS uropathogens, and across a range of key subgroups.
引用
- Sheets A, Dennison J, Han JH, et al. Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin. Clin Infect Dis. 2026. PMID: 42413960. doi:10.1093/cid/ciag408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。